您当前所在的位置:首页 > 产品中心 > 产品详细信息
42924-53-8 分子结构
点击图片或这里关闭

4-(6-methoxynaphthalen-2-yl)butan-2-one

ChemBase编号:344
分子式:C15H16O2
平均质量:228.28634
单一同位素质量:228.11502975
SMILES和InChIs

SMILES:
O(c1cc2c(cc(CCC(=O)C)cc2)cc1)C
Canonical SMILES:
COc1ccc2c(c1)ccc(c2)CCC(=O)C
InChI:
InChI=1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
InChIKey:
BLXXJMDCKKHMKV-UHFFFAOYSA-N

引用这个纪录

CBID:344 http://www.chembase.cn/molecule-344.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
4-(6-methoxynaphthalen-2-yl)butan-2-one
IUPAC传统名
nabumetone
商标名
Arthaxan
Balmox
Consolan
Dolsinal
Flambate
Listran
Mebutan
Nabuser
Prodac
Relafen
Relif
Relifen
Relifex
Unimetone
别名
4-(6-甲氧基-2-萘基)-2-丁酮
萘丁美酮
Nabumetonum [INN-Latin]
Nabumetona
Nabumetone
4-(6-Methoxy-2-naphthyl)-2-butanone
Nabumetone
Arthaxan
Relafen
CAS号
42924-53-8
MDL号
MFCD00079518
PubChem SID
24897772
46507729
160963807
PubChem CID
4409

理论计算性质

理论计算性质

ALOGPS 2.1 JChem
Log P 3.41  LOG S -5.07 
溶解度 1.93e-03 g/l 
Log P 3.2169938  摩尔折射率 68.4311 cm3
极化性 27.843512 Å3 极化表面积 26.3 Å2
可自由旋转的化学键 里宾斯基五规则 true 
Acid pKa 19.59154  质子受体
质子供体 LogD (pH = 5.5) 3.2169938 
LogD (pH = 7.4) 3.2169938 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
Practically insoluble expand 查看数据来源
疏水性(logP)
3.1 expand 查看数据来源
保存条件
Room Temperature (15-30°C) expand 查看数据来源
RTECS编号
EL9085000 expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
德国WGK号
2 expand 查看数据来源
个人保护装置
Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter expand 查看数据来源
作用靶点
COX expand 查看数据来源
相关基因信息
human ... PTGS1(5742), PTGS2(5743) expand 查看数据来源
级别
analytical standard expand 查看数据来源
成盐信息
Free Base expand 查看数据来源
质检报告
下载链接 expand 查看数据来源
Empirical Formula (Hill Notation)
C15H16O2 expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank Sigma Aldrich Sigma Aldrich
DrugBank -  DB00461 external link
Item Information
Drug Groups approved
Description Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid family (which includes diclofenac). Marketed under the brand name Relafen, it has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAIDs.

Indication For acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Pharmacology Nabumetone is a naphthylalkanone. Is is a non-selective prostaglandin G/H synthase (a.k.a. cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to prostaglandin G2 and prostaglandin G2 to prostaglandin H2. Prostaglandin H2 is the precursor to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. The parent compound is a prodrug that undergoes hepatic biotransformation to the active compound, 6-methoxy-2-naphthylacetic acid (6MNA). The analgesic, antipyretic and anti-inflammatory effects of NSAIDs occur as a result of decreased prostaglandin synthesis.
Toxicity The one overdose occurred in a 17-year-old female patient who had a history of abdominal pain and was hospitalized for increased abdominal pain following ingestion of 30 nabumetone tablets (15 grams total). Stools were negative for occult blood and there was no fall in serum hemoglobin concentration. The patient had no other symptoms.
Affected Organisms
Humans and other mammals
Biotransformation Undergoes rapid biotransformation to the principal active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine.
Absorption Well absorbed from the gastrointestinal tract. Coadministration of food increases the rate of absorption and subsequent appearance of 6MNA (the active metabolite) in the plasma but does not affect the extent of conversion of nabumetone into 6MNA.
Half Life Approximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency.
Protein Binding The active metabolite, 6MNA, is more than 99% bound to plasma proteins.
Elimination Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine.
Clearance * 20 - 30 mL/min
External Links
Wikipedia
RxList
PDRhealth
Drugs.com
Sigma Aldrich -  N6142 external link
Biochem/physiol Actions
非选择性非甾体抗炎药 (NSAID)

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
    暂无数据
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle